While low expression of ACSL4 has poor prognosis in lung cancer (RFS: total number, 204; 95% CI, 0.22–0.71, HR, 0.40; Cox P, 0.008784533), brain cancer (OS: total number, 70; 95% CI, 0.41–0.99, HR, 0.63.11; Cox P, 0.0457,155) and breast cancer (DSS: total number, 159; 95% CI, 0.22–0.85, HR, 0.43; Cox P, 0.0158,694; OS: total number, 159; 95% CI, 0.28–0.90, HR, 0.50; Cox P, 0.0205,638). This evidence concerns the gene ACSL4 and breast cancer.